This company listing is no longer active
MITRA Overzicht aandelen
Develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Mithra Pharmaceuticals SA Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €0.22 |
| 52 Week Hoogtepunt | €2.29 |
| 52 Week Laag | €0.20 |
| Bèta | 0.51 |
| 11 maand verandering | 0% |
| 3 maanden verandering | 0% |
| 1 Jaar Verandering | -90.11% |
| 33 jaar verandering | -98.79% |
| 5 jaar verandering | -99.27% |
| Verandering sinds IPO | -98.19% |
Recent nieuws en updates
Recent updates
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%
Apr 06
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive
Feb 07Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts
Nov 09These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts
Oct 05Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)
May 23Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts
Aug 11Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%
Mar 13Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt
Dec 22Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 24Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt
Jun 07When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?
May 10Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?
Mar 18We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings
Feb 16Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long
Jan 21
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 29Rendement voor aandeelhouders
| MITRA | BE Pharmaceuticals | BE Markt | |
|---|---|---|---|
| 7D | 0% | 2.7% | 0.6% |
| 1Y | -90.1% | 8.0% | 3.5% |
Rendement versus industrie: MITRA presteerde slechter dan de Belgian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 8 % opleverde.
Rendement versus markt: MITRA presteerde slechter dan Belgian Market, dat het afgelopen jaar een rendement van 3.5 % opleverde.
Prijsvolatiliteit
| MITRA volatility | |
|---|---|
| MITRA Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in BE Market | 6.3% |
| 10% least volatile stocks in BE Market | 2.4% |
Stabiele aandelenkoers: MITRA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van MITRA in het afgelopen jaar te bepalen.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 270 | Christophe Marechal | www.mithra.com |
Mithra Pharmaceuticals SA Samenvatting
| MITRA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €12.14m |
| Inkomsten(TTM) | -€173.50m |
| Inkomsten(TTM) | €40.16m |
0.4x
P/S-verhouding-0.1x
Koers/WinstverhoudingIs MITRA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MITRA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €40.16m |
| Kosten van inkomsten | €21.95m |
| Brutowinst | €18.21m |
| Overige uitgaven | €191.71m |
| Inkomsten | -€173.50m |
Laatst gerapporteerde inkomsten
Dec 31, 2023
Volgende inkomensdatum
Sep 26, 2024
| Winst per aandeel (EPS) | -2.51 |
| Brutomarge | 45.34% |
| Nettowinstmarge | -432.08% |
| Schuld/Eigen Vermogen Verhouding | -258.9% |
Hoe presteerde MITRA op de lange termijn?
Bekijk historische prestaties en vergelijking